Lv11
40 积分 2026-07-03 加入
Cancer burden and control in China: landscape, trends and challenges
6天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
P3.18.65 Trial in Progress - RAsolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in in Patients With Previously Treated RAS Mutant NSCLC
1个月前
已关闭
514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
1个月前
已完结
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
1个月前
已完结
皖公网安备34019202002308
